anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward preventing future losses from trauma exposure, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
FIELD: hygiene.SUBSTANCE: invention relates to compositions for oral care. Disclosed composition contains: a. basic amino acid in a free or salt form, where the basic amino acid is selected from arginine, lysine and a combination thereof; b. combination of sources of zinc ions and c. thickening system comprising: i. from 0.1 wt. % to 0.4 wt. % of hydroxyethyl cellulose by weight of composition for oral cavity care and ii. from 0.3 wt. % to 0.9 wt. % of xanthan gum by weight of the oral care composition, where hydroxyethyl cellulose is characterized by viscosity measured at 2 % in water at 25 °C of 4500 to 6500 cP.EFFECT: combination of components of thickening system provides optimum rheological properties of both preliminary mixtures in the form of gel, and final products - tooth-pastes.14 cl, 13 tbl, 8 ex
Clazosentan prevents vasospasms after aneurysmal subarachnoid hemorrhage (SAH). However, clinical data on patients with SAH with ruptured vertebral artery dissecting aneurysms (VADAs) are limited. We report the case of a 49-year-old male patient with mild-grade (WFNS grade 1) thick and diffuse (modified Fisher grade 3) SAH who underwent endovascular trapping of a ruptured VADA, resulting in a poor functional outcome with a modified Rankin Scale score of 4 due to severe symptomatic vasospasm refractory to clazosentan, requiring repeated rescue endovascular therapies and chronic communicating hydrocephalus. A retrospective analysis of the clot density in the basal and Sylvian cisterns, assessed by the Hounsfield unit (HU) values of serial CT scans, in this patient showed persistent higher values, distinct from another VADA case that showed a decline in HU values with a good clinical course. These results imply the limited effectiveness of clazosentan in cases of thick and diffuse SAH after a ruptured VADA, even in good-clinical-grade patients treated with less invasive modalities. The HU values may become a simple quantitative marker for predicting symptomatic vasospasms and chronic hydrocephalus.
PURPOSE:To provide a drug for oral cavity application, useful as a cariostatic agent free from side effects and having extremely high safety, by using a lactone as an active component. CONSTITUTION:The objective agent contains a lactone (e.g. d-decalactone, d- dodecalactone, d-undecalactone, d-tridecalactone, d-tetradecalactone, etc.) as an active component. The antibacterial activity of lactone to Streptococcus mutans causing caries is relatively low compared with an antibiotic substance, erythromycin; however, there is no side effects (disturbance of the microflora in the body, emergence of resistant strain, etc.) of antibiotic substances because the compound is a high-safety flavor component used widely in food industry, etc., and the agent can be administered continuously for a long period absolutely without problems. Since the agent inhibits the growth of Streptococcus mutans at an extremely low concentration, a cariostatic effect can be attained by the use of only a slight amount of the compound. It is used as a flavor of gargle, troche, dentifrice, etc.
An electronic insulin delivery device receives glucose data from a glucose monitor and sets a bolus dose amount. The device may take the form of an insulin pen with automatic priming and accurate dosing provided by a motor in connection with an encoder. The device may communicate with and be controlled by a smart phone device. The smart phone device provides a user interface to receive user data including patient weight, insulin to carbohydrate ratio and exercise factor, and to send instructions to the device, including dose amount. The dose amount is determined taking into account glucose level and trend, and other factors. The delivery device may be in continuous communication with the glucose monitor and smart phone to provide for near real-time adjustments in glucose treatment. Glucose data, insulin injection data, and other relevant data may be stored and accessible to interested parties.
Physical capacity and physical activity are important factors for healthy aging and are found to be predictors of disability, morbidity and mortality in healthy older adults and in people with chronic diseases like Parkinson's Disease and COPD. Physical capacity and activity have mainly been assessed in in-clinic settings using standardized tests and subjective questionnaires. Relying only on in-clinic tests is suboptimal because the tests give limited information on how a patient functions in daily life and cannot capture fluctuations and subtle decrements in disease symptoms. With the rise of innovative technology like wearable sensors, both aspects have become measurable in the patients daily life.

Here, the investigators will study a wrist worn device (The Verily Study Watch) that has the ability to measure physical activity and physical capacity passively and remotely. The primary focus is on its opportunity to measure physical capacity using the 6MWT, referred to as the virtual 6MWT. The watch tags the start and end of the 6 minutes when performing this test. Also, participants can perform the test independently at home. The Study Watch has the options for remote testing of the Timed Up and Go test (TUG) as well. The aim of this study is to investigate whether the virtual 6MWT validly predicts 6MWT outcomes as measured during a supervised, in-clinic test. A valid virtual 6MWT will be extremely valuable for assessing physical capacity in the home situation longitudinally. This will contribute to a more effective and personalized treatment for people with chronic diseases.

The study has a duration of 15 weeks, with 4 in-clinic visits at the physiotherapy practice every five weeks. During those visits, several physical capacity tests will be performed alongside tests and questionnaires related to demographics and disease status. Participants will perform the 6MWT and TUG at home on a weekly basis on a pre-set day and time using the Verily Study Watch. Between week 5 and 15 of the study, participants will follow a standardized aerobic exercise training program according to the most recent regulations.
Bladder cancer remains a leading cause of cancer death worldwide and is associated with substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare system. Gross hematuria frequently precedes the diagnosis of bladder cancer. Non-muscle-invasive bladder cancer (NMIBC) is managed initially with transurethral resection of a bladder tumor (TURBT), followed by a risk stratified approach to adjuvant intravesical therapy (IVe), and is associated with an overall survival of 90%. However, cure rates remain lower for muscle invasive bladder cancer (MIBC) owing to a variety of factors. NMIBC and MIBC groupings are heterogeneous and have unique pathological and molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers and luminal and basal molecular subtypes of MIBC with distinct treatment responses. For NMIBC, IVe immunotherapy (primarily BCG) is the gold standard treatment for high grade and high risk NMIBC to reduce or prevent both recurrence and progression after initial TURBT; novel trials incorporate immune checkpoint inhibitors. IVe gene therapy and combination IVe chemotherapy have recently been completed, with promising results. For localized MIBC, essential goals are improving care and reducing morbidity following cystectomy or bladder preserving strategies. In metastatic disease, advances in understanding of the genomic landscape and tumor microenvironment have led to the implementation of immune checkpoint inhibitors, targeted treatments, and antibody-drug conjugates. Defining better selection criteria to identify the patients most likely to benefit from a specific treatment is an urgent need.
PROBLEM TO BE SOLVED: To obtain a new compound having an excellent depression against endothelial tylosis and useful e.g. as a preventive and a therapeutic agent for the restenosis of blood vessel after the percutaneous coronary arteries-plasty. SOLUTION: This compound is expressed by formula I [wherein, R<1> is a lower alkyl, an aryl, or the like; R<2> is H, a lower alkyl, or the like; a group expressed by formula II is a group expressed by formula III or formula IV (wherein, R<3> is H, a halogen, or the like)], e.g. N-phenyl-3,3-di(2-pyridyl)-acrylic acid amide. The compound of formula I is obtained e.g. by reacting an amino compound (e.g. aniline) with a keto compound (e.g. bromoacetyl chloride) in a solvent in the presence of a base to form an amide compound (e.g. N-phenyl- bromoacetic acid amide), followed by reacting it with triethyl phosphite to form a compound of formula V (e.g. N-phenyl-diethyl phosphonoacetic acid amide), which is reacted with di-2-pyridyl ketone in a solvent in the presence of a base. The compound of formula I is pref. dispensed in a quantity of 0.5-100 mg/kg/day.
PURPOSE: A novel antibiotic compound and an agrochemical compound composition containing the same are provided to treat or prevent plant pathogen of crops. CONSTITUTION: A novel antibiotic compound is denoted by chemical formula 3. The compound of chemical formula 3 suppresses malonyl-CoA: acyl carrier protein transacylase(MCAT) activation. A pharmaceutical composition for preventing or treating pathogen contains the compound of chemical formula 3 and pharmaceutically acceptable carrier. A feed composition for preventing or treating infection by pathogen contains the compound of chemical formula 3 and acceptable carriers. An agrochemical composition for preventing or treating infection contains the compound of chemical formula 1 or 2 and agrochemically acceptable carriers.
A prospective longitudinal study will be carried out with three groups of patients: a group of euthymic bipolar I or II patients without cognitive impairment (n=50), a second group of euthymic bipolar I or II patients with cognitive impairment (n=50) and a control group of healthy volunteers (n=50). Cognitive impairment will be defined as performance in any test of a domain below 2 standard deviations or more from the mean of normative data of each test assessed in the control group. Subjects will be recruited in the Hospital Clinic of Barcelona. At baseline clinical variables and diet patterns (ROME III) will be collected and neuropsychological performance (WCST, FAS, Stroop Colour-Word Interference test, TMT, WAIS-III, CVLT-II) and functionality (FAST) will be assessed. All subjects will be reassessed at 12 months follow-up. The mood state and possible affective relapses will be evaluated and treatments will be registered. All patients will receive standard psychiatric care according to international guidelines on bipolar disorders. Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C until assayed. Sequencing will be performed on an Illumina MiSeqTM platform. Statistical analysis will be performed with the latest existing version of the SPSS.
Patients (n=23) on anticoagulant treatment with warfarin participated in a 27 weeks training program where they learned how to analyse International Normalised Ratio (INR) using the point-of-care instrument CoaguChek® XS and dose warfarin. The patients had to display their skills through a test before considered self-managing. They continued to measure INR weekly for 28 weeks. All INR values during the training program and self-control period were collected. In addition, the patients were told to notify if they had any complications during this period. Ten INR values and complications before enrolment was collected from INR cards and/or their general practioner. The participant filled in a quality of life-questioner at enrolment and after 28 weeks of self-management.
All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the control group (n=2000) will not participate in LST but will receive the sexual violence and substance abuse educational content normally provided by their schools.
Powdered formula containing whey protein and arginine (Active A) and placebo oil. Participants will mix the powder (Active A) with 250 mL of water and drink the formula 3 times per day for 5 days. Each drink will be followed by consuming 1 tsp of the lipid bolus. This will be done for 5 days prior to the operation and for 5 days after the operation.
Studies have underscored the pivotal role of metastasis-associated protein 3 (MTA3) as a cancer regulator, yet its potential as a drug target across cancers necessitates comprehensive evaluation. In this study, we analyzed MTA3 expression profiles to ascertain its diagnostic and prognostic value in pan-cancers, probing associations with genetic variations and immunological characteristics. Notably, liver hepatocellular carcinoma (LIHC) exhibited the most significant correlation with MTA3. By transfection of siRNA, interference of MTA3 affected HepG2 and Hepa1-6 cell viability and migration. Through drug screening and drug-likeness evaluation among marine-derived natural products, Jaspamycin was identified as a potential hepatocellular carcinoma treatment by targeting MTA3. By applying in vitro and in vivo experiment, the inhibitory effects of Jaspamycin on hepatocellular carcinoma viability, migration, and tumor progression were observed. To assess the potential of MTA3 as an anticancer drug target, MTA3 overexpression plasmid was transfected together with Jaspamycin treatment, and observed that MTA3 upregulation counteracted the inhibitory effects of Jaspamycin on hepatocarcinoma cell proliferation and migration, underscoring the efficacy of MTA3 as a drug target in hepatocellular carcinoma drug screening. This study highlights the clinical significance of MTA3 in pan-cancer, particularly in hepatocellular carcinoma. Additionally, it identifies Jaspamycin, a marine-derived compound with promising pharmacological properties, as an effective inhibitor of MTA3 activity, suggesting its potential for hepatocellular carcinoma treatment.
The ketogenic diet (KD) is marked by a substantial decrease in carbohydrate intake and an elevated consumption of fats and proteins, leading to a metabolic state referred to as "ketosis," where fats become the primary source of energy. Recent research has underscored the potential advantages of the KD in mitigating the risk of various illnesses, including type 2 diabetes, hyperlipidemia, heart disease, and cancer. The macronutrient distribution in the KD typically entails high lipid intake, moderate protein consumption, and low carbohydrate intake. Restricting carbohydrates to below 50 g/day induces a catabolic state, prompting metabolic alterations such as gluconeogenesis and ketogenesis. Ketogenesis diminishes fat and glucose accumulation as energy reserves, stimulating the production of fatty acids. Neurodegenerative diseases, encompassing Alzheimer's disease, Parkinson's disease are hallmarked by persistent neuroinflammation. Evolving evidence indicates that immune activation and neuroinflammation play a significant role in the pathogenesis of these diseases. The protective effects of the KD are linked to the generation of ketone bodies (KB), which play a pivotal role in this dietary protocol. Considering these findings, this narrative review seeks to delve into the potential effects of the KD in neuroinflammation by modulating the immune response. Grasping the immunomodulatory effects of the KD on the central nervous system could offer valuable insights into innovative therapeutic approaches for these incapacitating conditions.
Instructions for the Preparation of Technetium Tc 99m Red Blood Cells Injection UsingUltratag TMRBC

1\. Collect patient's blood sample (1.0 to 3.0 mL) using heparin or ACD as an anticoagulant. The amount of ACD should not exceed 0.15 mL of ACD per mL of blood. The recommended amount of heparin is 10-15 units per mL of blood. DO NOT USE EDTA OR OXALATE AS AN ANTICOAGULANT.

2\. Using a large-bore (19 to 21 gauge) needle, transfer 1.0 to 3.0 mL of anticoagulated whole blood to the reaction vial and gently mix to dissolve the lyophilized material. Allow to react for five minutes.

3\. Add contents of Syringe I, mix by gently inverting four to five times.

4\. Add the contents of Syringe II to the reaction vial. Mix by gently inverting four to five times.

5\. Place the vial in a lead shield fitted with a lead cap and having a minimum wall thickness of 1/8 inch. Add 370 to 3700 MBq (10 to 100 mCi) sodium pertechnetate Tc 99m (in a volume of up to 3 mL) to the reaction vial. The avoidance of long technetium Tc 99 in-growth times and the use of fresh sodium pertechnetate Tc 99m generator eluate is recommended.

6\. Mix by gently inverting reaction vial four to five times. Allow to react for 20 minutes with occasional mixing.

7\. Technetium Tc 99m red blood cells should be injected within 30 minutes of preparation or as soon as possible thereafter.

8\. If desired, assay labeling efficiency immediately prior to injection. Typical labeling efficiency is greater than 95%.

9\. Mix gently prior to withdrawal of patient dose. Aseptically transfer the technetium Tc 99m red blood cells to a syringe for administration to the patient. Use largest bore needle compatible with patient administration to prevent hemolysis.

10\. Assay the Tc 99m red blood cell patient dose in a suitable calibrator and complete the radioassay information label. Affix the radioassay information label to the shield.

NOTES

1\. The kit does not contain an anticoagulant. Therefore, a syringe treated with ACD or heparin must be used for drawing the patient's blood. The amount of ACD should not exceed 0.15 mL of ACD per mL of blood. The recommended amount of heparin is 10-15 units per mL of blood. Improperly anticoagulated blood will be unsuitable for reinjection.

2\. If desired, the labeling yield determination can be carried out as follows:

Transfer 0.2 mL of the technetium Tc 99m red blood cells to a centrifuge tube containing 2 mL of 0.9% NaCl. Centrifuge for five minutes and carefully pipet off the diluted plasma. Measure the radioactivity in the plasma and red blood cells separately in a suitable counter. Calculate labeling efficiency as follows:

This reagent kit is approved for distribution to persons licensed by the U.S. Nuclear Regulatory Commission to use byproduct material identified in Section 10 CFR 35.200 or under an equivalent license of an Agreement state.

©2024 Curium US LLC. Ultratag TMRBC, Curium TM, and the Curium logo are trademarks of a Curium company. 

Manufactured by: Curium US LLC   
Maryland Heights, MO 63043 

Made in USA

A068I0

R05/2024

CURIUM TM
PURPOSE: A transformant which produces rotavirus VP7 antigen protein is provided to induce antibody formation with respect to rotavirus in human body using a vaccine, and to prevent rotavirus disease. CONSTITUTION: An expression vector contains VP7 antigen gene encoding rotavirus VP7 coat protein in sequence number 1. VP7 antigen gene has a nucleic acid sequence in sequence number 2. An expression vector is VP7/pB7WG2D vector. An Agrobacterium sp. microorganism is transformed by the expression vector. A transformant is prepared by the microorganism. A recombinant rotavirus VP7 antigen protein is expressed from the transformant. A vaccine composition for oral administration for preventing and treating rotavirus diseases contains the transformant, a protein extract of the transformant, or the recombinant rotavirus VP7 antigen protein as an active ingredient. [Reference numerals] (AA) BP reaction; (BB) LP reaction
Ambient sound can mask acoustic signals. The current study addressed how echolocation in people is affected by masking sound, and the role played by type of sound and spatial (i.e. binaural) similarity. We also investigated the role played by blindness and long-term experience with echolocation, by testing echolocation experts, as well as blind and sighted people new to echolocation. Results were obtained in two echolocation tasks where participants listened to binaural recordings of echolocation and masking sounds, and either localized echoes in azimuth or discriminated echo audibility. Echolocation and masking sounds could be either clicks or broad band noise. An adaptive staircase method was used to adjust signal-to-noise ratios (SNRs) based on participants' responses. When target and masker had the same binaural cues (i.e. both were monoaural sounds), people performed better (i.e. had lower SNRs) when target and masker used different types of sound (e.g. clicks in noise-masker or noise in clicks-masker), as compared to when target and masker used the same type of sound (e.g. clicks in click-, or noise in noise-masker). A very different pattern of results was observed when masker and target differed in their binaural cues, in which case people always performed better when clicks were the masker, regardless of type of emission used. Further, direct comparison between conditions with and without binaural difference revealed binaural release from masking only when clicks were used as emissions and masker, but not otherwise (i.e. when noise was used as masker or emission). This suggests that echolocation with clicks or noise may differ in their sensitivity to binaural cues. We observed the same pattern of results for echolocation experts, and blind and sighted people new to echolocation, suggesting a limited role played by long-term experience or blindness. In addition to generating novel predictions for future work, the findings also inform instruction in echolocation for people who are blind or sighted.
These studies will provide a comprehensive test of our proposed model of alcohol-involved sexual assault that includes situation-specific mechanisms and key moderators of sexual violence. Specifically, hypotheses will be tested in the context of two carefully controlled laboratory studies. In Study 1, laboratory alcohol administration procedures will be used to manipulate intoxication (vs. placebo control) in men. Impaired attention and objectification will then be measured multi-modally including behavioral, self-report, and implicit measures. Finally, sexual aggression will be measured with a laboratory-based analogue of sexual assault. Study 2 will include women and follow the same alcohol administration procedures as Study 1. Additionally, mirroring men's objectification, objectifying gazes (vs. eye gazes) will also be manipulated. Impaired attention, self-objectification, and decreased sexual risk perceptions will then be assessed. Prior the laboratory visit, all participants will complete a battery of questionnaires to assess key moderators including a history of sexual assault perpetration and victimization, prior sexual objectification and self-objectification, as well as alcohol-related sex expectances and rape myth acceptance. The overall model will be analyzed within a conditional process model framework.